AASLD 2011: Sustained Response is Durable among Hepatitis C Patients Treated with Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
- Written by Liz Highleyman
Almost all chronic hepatitis C patients who achieved sustained virological response (SVR) using the recently approved HCV protease inhibitor telaprevir (Incivek) plus pegylated interferon and ribavirin continued to have undetectable viral load nearly 2 years later, according to data presented at the recent American Association for the Study of Liver Disease (AASLD) Liver Meeting in San Francisco.
AASLD 2011: Fever Signals Responsiveness to Pegylated Interferon for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
People who have an increase in body temperature soon after starting interferon-based therapy for chronic hepatitis C virus (HCV) infection are more likely to experience early virological response, according to a presentation at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
AASLD 2011: Natural History of Hepatitis B Infection and Role of HBV Genotype
- Details
- Category: Hepatitis B
- Published on Tuesday, 20 December 2011 00:00
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive and negative disease have different levels of hepatitis B surface antigen (HBsAg), variable extent of liver fibrosis, and different distribution of HBV genotypes, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 December 2011 00:00
- Written by Transgene
Transgene's recombinant poxvirus therapeutic hepatitis C virus (HCV) vaccine, TG4040, demonstrated good tolerability and increased the likelihood of viral suppression at 12 weeks when administered with pegylated interferon plus ribavirin, according to data from an international Phase 2 clinical trial reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in San Francisco. 
AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
- Written by Liz Highleyman
The hepatitis C virus (
HCV) NS3/4A protease inhibitor danoprevir (formerly RG7128) plus pegylated interferon/ribavirin produced high cure rates and many patients were eligible for shorter therapy, according to findings presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
More Articles...
- AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients
- AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
Web Design and Development by